Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with fast...

Descripción completa

Detalles Bibliográficos
Autores principales: McEwan, Phil, Webster, Samantha, Ward, Thomas, Brenner, Michael, Kalsekar, Anupama, Yuan, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521139/
https://www.ncbi.nlm.nih.gov/pubmed/28736505
http://dx.doi.org/10.1186/s12962-017-0077-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521139/
https://www.ncbi.nlm.nih.gov/pubmed/28736505
http://dx.doi.org/10.1186/s12962-017-0077-4

Ejemplares similares